|
**Overview**: Endomysial Antibody IgA Dilutions Panel**Introduction**: The Endomysial Antibody IgA Dilutions Panel is a diagnostic tool designed to quantify celiac disease antibodies using serum samples. In India, celiac disease prevalence is ~0.5-1 percent, with EMA IgA titer providing prognostic value (higher titers correlate with severe villous atrophy) and monitoring response to gluten-free diet. High morbidity from under-quantification in rural/low-SES patients, limited titer assays, delayed adherence leading to persistent malabsorption or complications. Per immunology practices aligned with ICMR and Indian Society of Gastroenterology guidelines, the test employs immunoassay with serial dilutions for EMA IgA titer over 1-2 days with high accuracy, valuable for confirming and monitoring celiac disease. This diagnostic falls under autoimmune screening and targets patients with positive qualitative EMA IgA or suspected celiac, addressing accurate quantification to guide biopsy urgency and diet compliance. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise disease assessment and reducing long-term complications. Its serum-based approach ensures reliable titer determination.**Other Names**: Endomysial Dil Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: EMA titer for severity/monitoring; in India, used in celiac follow-up.**Purpose**: The test assesses 2 parameters including endomysial IgA titer to guide celiac disease quantification, monitor response, inform management.**Test Parameters**: 1. Endomysial IgA Titer, 2. Quantitative Result.**Pretest Condition**: No fasting required; patients should report positive EMA or celiac symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, prior EMA result, gluten intake.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated celiac including malabsorption, benefits of quantification, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay with dilutions by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or IgA deficiency can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High titer indicates active celiac, necessitating specialist input. Declining titer suggests diet response.**Specialist Consultation**: Gastroenterologists should be consulted for management.**Additional Supporting Tests**: Anti-tTG IgA, biopsy for confirmation.**Test Limitations**: Titer interpretation needs clinical context; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, Celiac Studies India 2023. |
